Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study.
Okauchi S, Numata T, Nawa T, Ichimura H, Saito T, Hayashihara K, Yamada H, Satoh H, Endo T, Inage Y, Kaburagi T, Kiyoshima M, Yamada Y, Tamura T, Saito K, Inagaki M, Hizawa N, Sato Y, Shiozawa T, Sekine I, Ishikawa H, Kurihima K, Sakai M, Kamiyama K, Kimura M, Kikuchi N, Nakamura H, Furukawa K, Kodama T, Miyazaki K, Yamashita T, Hayashi S, Funayama Y, Nomura A. Okauchi S, et al. Among authors: numata t. Anticancer Res. 2020 Feb;40(2):957-964. doi: 10.21873/anticanres.14029. Anticancer Res. 2020. PMID: 32014940
Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients.
Miyazaki K, Sato S, Kodama T, Numata T, Endo T, Yamamoto Y, Shimizu K, Yamada H, Hayashihara K, Okauchi S, Satoh H, Yamada Y, Tamura T, Saito K, Kikuchi N, Kurishima K, Ishikawa H, Watanabe H, Shiozawa T, Hizawa N, Funayama Y, Hayashi S, Nakamura H, Yamashita T. Miyazaki K, et al. Among authors: numata t. In Vivo. 2020 Jul-Aug;34(4):2001-2007. doi: 10.21873/invivo.11998. In Vivo. 2020. PMID: 32606173 Free PMC article.
Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer.
Shiozawa T, Numata T, Tamura T, Endo T, Kaburagi T, Yamamoto Y, Yamada H, Kikuchi N, Saito K, Inagaki M, Kurishima K, Funayama Y, Miyazaki K, Koyama N, Furukawa K, Nakamura H, Kikuchi S, Ichimura H, Sato Y, Sekine I, Satoh H, Hizawa N. Shiozawa T, et al. Among authors: numata t. Anticancer Res. 2022 May;42(5):2583-2590. doi: 10.21873/anticanres.15736. Anticancer Res. 2022. PMID: 35489768
Atezolizumab Monotherapy for Non-small Cell Lung Cancer Patients: An Observational Study in Ibaraki Group (ATTENTION-IBARAKI).
Okauchi S, Ohara G, Shiozawa T, Watanabe H, Numata T, Nakamura R, Tamura T, Kikuchi N, Miyazaki K, Hayashi S, Sakurai H, Yamashita T, Kurishima K, Inagaki M, Endo T, Ishikawa H, Kaburagi T, Satoh H, Sakamoto T, Hizawa N. Okauchi S, et al. Among authors: numata t. In Vivo. 2023 Sep-Oct;37(5):2203-2209. doi: 10.21873/invivo.13320. In Vivo. 2023. PMID: 37652502 Free PMC article.
Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI).
Tamura T, Numata T, Yanai H, Nakamura R, Shiozawa T, Watanabe H, Okauchi S, Kikuchi N, Miyazaki K, Hayashi S, Yamashita T, Kurishima K, Inagaki M, Satoh H, Ishikawa H, Kaburagi T, Endo T, Sakamoto T, Hizawa N. Tamura T, et al. Among authors: numata t. Anticancer Res. 2023 Oct;43(10):4583-4591. doi: 10.21873/anticanres.16652. Anticancer Res. 2023. PMID: 37772562
492 results